University of Utah startups continue innovating and discovering solutions to today’s unmet needs. Here’s a roundup of some of the latest news out of these companies:
Utah Innovation Fund invests $700k in local health care, life sciences startups
As part of a new partnership, 3Helix, Rebel Medicine, and Inherent Biosciences were recently awarded a collective $700K in funding by the Utah Innovation Fund, a state-backed venture capital fund. 3Helix is a part of the University of Utah’s startup portfolio, Rebel Medicine was founded by a U grad, and Inherent Biosciences is a joint development with BYU and the U.
“The Utah Innovation Fund is deeply committed to fostering the advancement of pioneering technologies, and these companies have made significant strides in the field of biomedical innovation,” said Gabi Tellez, managing director for the Utah Innovation Fund.
Innovation Fund Managing Director Jefferson Moss agreed, adding, “We want to make an impact with the funds we invest in to solve some of today’s biggest problems, and the talented teams at 3Helix, Rebel Medicine, and Inherent Biosciences are finding those cutting-edge solutions.”
Inherent Biosciences and Genomic Prediction Announce Commercial Partnership to Advance Male Reproductive Health
Inherent Biosciences, Inc. and Genomic Prediction, Inc. (North Brunswick, NJ) are thrilled to announce a comprehensive commercial partnership agreement. This collaboration is set to advance male reproductive health by integrating Inherent Biosciences' groundbreaking Epigenetic Sperm Quality Test (SpermQT™ marketed under the brand Path Fertility) into Genomic Prediction's robust suite of clinical laboratory tests.
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024.
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced it has completed the acquisition from Intermountain Health of select assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah.
BD, Techcyte Announce Strategic Collaboration to Offer AI-Based Digital Cervical Cytology System for Pap Testing
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Techcyte, a world leader in artificial intelligence (AI)-based digital diagnostics, announced a strategic collaboration agreement to offer an AI-based algorithm that guides cytologists and pathologists to efficiently and effectively identify evidence of cervical cancer and precancer using whole-slide imaging.